SAShahideh Amini

Shahideh Amini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shahideh Amini has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Alireza Naserian

    Faculty of Medicine, Department of Internal Medicine Tehran University of Medical Science (TUMS) Tehran Iran

    2 shared publications
  • Amin Pastaki Khoshbin

    School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Azin Abdollahi

    Faculty of Pharmacy Tehran University of Medical Science (TUMS) Tehran Iran

    2 shared publications
  • Hadieh Tazerouni

    Faculty of Pharmacy Tehran University of Medical Science (TUMS) Tehran Iran

    2 shared publications
  • Hooman Bakhshandeh

    Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Katayoun Najafizadeh

    Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications

Latest Publications

  • Open Access

    Flipped classroom showdown: game-based vs. case-based learning in pharmacy education

    by Mahtab Amini, Shahideh Amini, Maryam Alizadeh

    Active learning methods like flipped classrooms, case-based learning (CBL), and game-based learning (GBL) are increasingly important in medical and pharmac

  • Open Access

    A Case Report of Drug‐Induced Hemorrhagic Bullae

    by Mehrdad Shavandi, Zohre Labbani‐Motlagh, Azin Abdollahi, Hadieh Tazerouni, Alireza Naserian, Shahideh Amini

    Hemorrhagic bullae is a rare, non‐immune, cutaneous adverse reaction that happens after the administration of some medicine. This case is a unique report of vancomycin and alteplase‐induced hemorrhagic bullae and warns physicians and healthcare teams to take action properly.

  • Open Access

    Effect of melatonin on insomnia and daytime sleepiness, in patients with obstructive sleep apnea and insomnia (COMISA): A randomized double-blinded placebo-controlled trial

    by Tahereh Madani Motlaq, Besharat Rahimi, Shahideh Amini

    Background: COMISA is a common disorder that results in nighttime awakenings ,daytime sleepiness and PAP intolerance. Cognitive behavioral therapy for insomnia is used to improve PAP adherence and no medication has been evaluated in such population yet. Melatonin with its chronobiotic and antioxidant effects may have potential benefits on COMISA consequences at the appropriate dose and time. This study aimed to evaluate the effect of melatonin on sleep quality, daytime sleepiness and PAP Compliance in patients with COMISA. Methods: This double-blind placebo trial randomly assigned eligible OSA patients who suffered from insomnia despite using PAP for over a month to receive either melatonin 10 mg or placebo. The primary outcomes were measured by changes in the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ-10) over one month. Adherence to PAP was measured by the results of the PAP device reports on the average length of time and number of nights that the device was used. Results: Thirty patients were enrolled in the study after randomization. The melatonin arm showed significant improvement in all four primary outcomes compared to the placebo arm. The PSQI score was 3.836±1.839 in the melatonin arm versus 10.522±3.626 in the placebo arm (PvaluePvaluePvaluePvalue= 0.006). Additionally, nighttime consequences such as sleep latency and awakenings showed significant improvement in the melatonin arm. PAP devices results revealed improvement in duration of PAP use overnight. Conclusions: Administering melatonin has been shown to improve self-reported sleep quality and PAP adherence in patients with COMISA. Trial registration: Registration number IRCT20220105053635N1 was issued by the Iranian Registry of Clinical Trials (IRCT).


  • Open Access

    A case report of drug-Induced hemorrhagic bullae

    by Mehrdad Shavandi, Zohre Labbani-Motlagh, Hadieh Tazerouni, Alireza Naserian, Azin Abdollahi, Shahideh Amini

    A case report of drug-Induced hemorrhagic bullae

  • Open Access

    A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS)

    by Naeemeh Dini, Amin Pastaki Khoshbin, Rasoul Aliannejad, Hooman Bakhshandeh, Katayoun Najafizadeh, Mahshid Mehdizadeh, Shahideh Amini

    Background: Despite the fundamental progress in hematopoietic stem cell transplant, this treatment is also associated with complications. Graft-versus-host disease is a possible complication of HSCT. Bronchiolitis obliterans syndrome (BOS) is the pulmonary form of this syndrome. Due to the high morbidity and mortality rate of BOS, various studies have been conducted in the field of drug therapy for this syndrome, although no standard treatment has yet been proposed. According to the hypotheses about the similarities between BOS and chronic obstructive pulmonary disease, the idea of using tiotropium bromide as a bronchodilator has been proposed. Method/design: A randomized, double-blind, placebo-controlled, and crossover clinical trial is being conducted to evaluate the efficacy of tiotropium in patients with BOS. A total of 20 patients with BOS were randomly assigned (1:1) to receive a once-daily inhaled capsule of either tiotropium bromide (KP-Tiova Rotacaps 18 mcg, Cipla, India) or placebo for 1 month. Patients will receive tiotropium bromide or placebo Revolizer added to usual standard care. Measurements will include spirometry and a 6-min walking test. Ethics/dissemination: This study was approved by the Research Ethics Committees of Imam Khomeini Hospital Complex, Tehran University of Medical Science. Recruitment started in September 2022, with 20 patients randomized. The treatment follow-up of participants with tiotropium is currently ongoing and is due to finish in April 2024. The authors will disseminate the findings in peer-reviewed publications, conferences, and seminar presentations. Trial registration: Iranian Registry of Clinical Trial (IRCT) IRCT20200415047080N3. Registered on 2022–07-12, 1401/04/21.


  • Open Access

    A placebo-controlled, crossover trial to investigate the efficacy of Tiotropium Bromide or Placebo added to usual care in stable symptomatic post-Hematopoietic Stem Cell Transplantation (HSCT) Bronchiolitis Obliterans Syndrome (BOS)

    by Naeemeh Dini, Amin Pastaki Khoshbin, Rasoul Aliannejad, Hooman Bakhshandeh, Katayoun Najafizadeh, Mahshid Mehdizadeh, Shahideh Amini

    Background: Despite the fundamental progress in Hematopoietic stem cell transplant, this treatment is also associated with complications. Graft versus Host Disease is a possible complication of HSCT. Bronchiolitis obliterans syndrome (BOS) is the pulmonary form of this syndrome. Due to the high morbidity and morbidity rate of BOS, various studies have been conducted in the field of drug therapy for this syndrome, although no standard treatment has yet been proposed. According to the hypotheses about the similarities between BOS and chronic obstructive pulmonary disease, the idea of using tiotropium bromide as a bronchodilator has been proposed. Method/design: A randomized, double-blind, placebo-controlled, and crossover clinical trial is being conducted to evaluate the efficacy of tiotropium in patients with BOS. A total of 20 patients with BOS, were randomly assigned (1:1) to receive a once-daily inhaled capsule of either Tiotropium bromide (KP-Tiova Rotacaps 18 mcg; Cipla; India) or placebo for 1 month. Patients will receive Tiotropium Bromide or placebo Revolizer added to usual standard care. Measurements will include spirometry, six-minute walking test. Ethics/dissemination: This study was approved by the Research Ethics Committees of Imam Khomeini Hospital Complex, Tehran University of Medical science. Recruitment started in September 2022, with 20 patients randomized. The treatment follow-up of participants with Tiotropium is currently ongoing and is due to finish in December 2023. The authors will disseminate the findings in peer-reviewed publications, conferences and seminar presentations. Trial registration: Iranian registry of clinical trial IRCT registration number: IRCT20200415047080N3 Registration date: 2022-07-12, 1401/04/21

  • Anticoagulation strategies and clinical outcomes in critically ill SARS-CoV-2 patients: A retrospective cohort study

    by Shahideh Amini, Mahshad Kazemi, Ghazal Roostaei, Niloofar Khoshnam Rad

    Background: COVID-19 is associated with a hypercoagulable state leading to an increased risk of thrombotic events. Although anticoagulation therapy is widely used, the optimal dosing strategy remains uncertain. Objective: The aim of this study was to evaluate the impact of therapeutic versus prophylactic anticoagulation on outcomes in critically ill COVID-19 patients. Methods: A retrospective cohort study was conducted on 315 critically ill COVID-19 patients. Patients were divided into two groups based on their anticoagulation regimen: therapeutic dose and prophylactic dose. The primary outcome was in-hospital mortality, while secondary outcomes included major bleeding events, thromboembolic events, and mechanical ventilation requirements. Results: No significant difference in mortality was observed between the therapeutic and prophylactic anticoagulation groups. Additionally, there were no significant differences in secondary outcomes. Conclusion: Our findings suggest that therapeutic anticoagulation may not provide a significant survival benefit compared to prophylactic anticoagulation in critically ill COVID-19 patients. To optimize patient outcomes, a more tailored approach to anticoagulation may be necessary, taking into account individual patient factors and risk assessment. Further prospective studies are needed to definitively establish the optimal anticoagulation strategy, especially in the context of evolving treatment modalities and vaccinations.

  • Open Access

    A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms

    by Nastaran Kordjazy, Shahideh Amini

    Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic pulmonary and hematological diseases, respectively. One of the complications in these patients is the development of bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms have been recognized for BOS in lung transplant and graft- versus-host disease (GVHD) patients involving the TH-1 and TH-2 cells, NF-kappa B, TGF-b, several cytokines and chemokines, and cysteinyl leukotrienes (CysLT). Montelukast is a highly selective CysLT receptor antagonist that has been demonstrated to exert anti-inflammatory and anti-fibrotic effects in abundant experiments. One area of interest for the use of montelukast is lung transplants or GVHD-associated BOS. Herein, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS, and finally, the possible relationship between CysLTs antagonism and BOS improvement will be discussed.


  • Open Access

    Rapid implementation of telepharmacy service to improve patient‐centric care and multidisciplinary collaboration across hospitals in a COVID era: A cross‐sectional qualitative study

    by Niloofar Khoshnam‐Rad, Marsa Gholamzadeh, Mehrnaz Asadi Gharabaghi, Shahideh Amini

    Background and Aim: The COVID‐19 pandemic forced healthcare systems to apply new technology‐based solutions. The main objective of our study was to describe the conceptual model for rapid implementation of telepharmacy service and the main steps that should be considered.Method: In response to a limited number of on‐site clinical pharmacy specialists and a lack of technology infrastructure, a cross‐sectional telepharmacy program was established to support major teaching hospitals. A store and forward model of teleconsultation was employed using WhatsApp messenger to cover various aspects of multidisciplinary collaboration in COVID‐19 management. All identifiable personal information was removed from all exchanged messages of collaborative consultations. The thematic analysis of consultations was performed to extract the main themes and subthemes that should be considered for designing future telepharmacy systems.Results: Through telepharmacy service, 600 intensive care unit teleconsultations for COVID‐19 cases were conducted in the residence center and nonresidence centers. In total, 1200 messages were exchanged between specialists in 3 months. The average time taken to respond to a message was 1.30 h. Thematic analysis revealed four main concepts and 15 subconcepts that should be considered in telepharmacy consultations for COVID‐19 management. Based on the extracted themes, a conceptual model for developing a telepharmacy program was devised.Conclusion: The results showed that by utilizing telehealth, clinical pharmacists could cover critically ill patients who need pharmacotherapy counseling through interdisciplinary collaboration. Moreover, the main features of our service that are represented through this survey can be employed by other researchers for developing telepharmacy services.


  • Open Access

    Case series of nebulizing r‐tPA for COVID‐19 induced acute respiratory distress syndrome

    by Shahideh Amini, Zohre Labbani‐Motlagh, Rasoul Aliannejad, Seyed Mohammad Pourabbas, Mohammad Vasei

    Fibrin deposition in the alveolar spaces during pulmonary involvement of COVID‐19 impairs the O2/CO2 exchange and leads to respiratory symptoms. In this report, Recombinant Tissue Plasminogen Activator (r‐tPA) has been nebulized to 3 critically ill COVID‐19 patients in order to resolve the deposited fibrin while avoiding the risk of bleeding. Based on these observations, nebulization of r‐tPA may be a potential therapeutic approach and new area of research for future studies.